Sulfamethoxazole/Trimethoprim

Official Title
Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections: A Randomized, Double-Blind, Placebo-Controlled Trial
Brief Summary
Acute kidney injury (AKI) is commonly followed by infections after hospital discharge. This randomized, double-blind, placebo-controlled trial will test whether prophylactic TMP/SMX reduces post-discharge infections in adults recently hospitalized with AKI. Participants will be randomized 1:1 to TMP/SMX or matching placebo and followed for 6 months. The primary outcome is the proportion of participants who develop any infection within 90 days after discharge. Secondary outcomes include time to first infection, infection-related hospitalization, mortality, safety/adverse events, and healthcare utilization through 180 days.
Detailed Description
Adults discharged after an index hospitalization complicated by AKI are at elevated infection risk. This trial evaluates whether short-term TMP/SMX prophylaxis reduces 90-day infections. After consent and eligibility confirmation near discharge, participants are randomized (1:1) to receive TMP/SMX or matching placebo with double-blind masking (participant and outcome assessor). Dosing is standardized per protocol. We will ascertain infections via structured follow-up, medical record review, and adjudication by blinded assessors. Safety monitoring will capture adverse events (e.g., rash, cytopenias, hyperkalemia). Analyses follow intention-to-treat.
Study Design
* Study Type: Interventional (Clinical Trial)
* Primary Purpose: Prevention
* Allocation: Randomized (1:1)
* Intervention Model: Parallel Assignment
* Masking: Double-blind (Participant, Outcomes Assessor)
* Estimated Enrollment: 60 patients per group
* Study Start Date: December 2025
* Primary Completion Date (Anticipated): January 2027 (last patient reaches 90-day outcome)
* Study Completion Date (Anticipated): July 2028 (last patient completes 180-day follow-up)
Arms & Interventions
Experimental: TMP/SMX
* Intervention: Drug: Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours
* Dosing: One tablet by mouth, Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours, for 90 days post-discharge.
* Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F
Placebo Comparator: Placebo
* Intervention: Drug: Placebo (matching oral tablet)
* Dosing: Matching schedule for 90 days post-discharge.
Concomitant care: Allowed per treating clinician. Drug interactions and lab monitoring handled per protocol.
Outcome Measures
Primary Outcome
• Any infection within 90 days after discharge Time Frame: Day 0 (discharge) to Day 90 Measure: Proportion of participants with ≥1 infection, defined by clinical diagnosis requiring documentation (e.g., UTI, pneumonia, SSTI, bloodstream infection) and/or antimicrobial treatment initiation.
Secondary Outcomes
1. Time to first infection (days) within 90 days.
2. Infection-related hospitalization within 90 and 180 days.
3. All-cause mortality at 90 and 180 days.
4. Emergency department visits or unplanned readmissions within 180 days.
5. Antibiotic-related adverse events (rash, cytopenia, creatinine rise ≥0.3 mg/dL, hyperkalemia ≥5.5 mmol/L) through 180 days.
6. C. difficile infection within 180 days.
7. Recurrent AKI (KDIGO criteria) within 180 days.
8. Medication adherence (pill counts and/or self-report) over 90 days.
9. Major adverse kidney events over 90 days.
Eligibility Criteria
Inclusion Criteria
* Age ≥18 years.
* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.
* Planned discharge to community/rehabilitation with capacity for follow-up.
* Ability to provide informed consent.
Exclusion Criteria
* Known allergy to sulfonamides or TMP/SMX.
* Pregnancy or breastfeeding.
* Severe hepatic disease (e.g., Child-Pugh C).
* Severe cytopenia (e.g., ANC <1.0×10⁹/L or platelets <50×10⁹/L).
* Baseline hyperkalemia (>5.5 mmol/L) not correctable prior to randomization.
* Concomitant medications with high-risk interactions not amenable to dose/monitoring (per protocol).
* Current systemic antimicrobial therapy planned for >14 days after discharge (prophylaxis not indicated).
* Inability to adhere to study procedures or follow-up.
Contacts/Locations
* Lead Sponsor / Responsible Party: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología
* Principal Investigator: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología, 3313299609
* Study Locations: Hospital Civil de Guadalajara, servicio de Nefrología, Hospital 278, colonia el Retiro. Guadalajara. Jalisco.
Ethics and Oversight
* Conducted in accordance with the Declaration of Helsinki and ICH-GCP.
* IRB/Ethics approval: Comité de etica en investigacion, Protocol CEI 214/25, Approval : October 16, 2025.
* Written informed consent obtained from all participants prior to any study procedures.
* Data

Cesarean section refers to the surgical procedure in which the fetus is delivered via an incision, typically performed when vaginal delivery is not possible due to high-risk conditions. In recent years, the rate of cesarean deliveries has increased significantly. The quality of treatment and care is crucial in ensuring proper surgical wound healing following cesarean birth. Various new methods and products have been developed for wound healing and care in recent years, some of which are derived from herbal sources. The limitations of pharmacological methods used in the postpartum period, such as treatment failure, concerns about potential harm to the mother and infant, adverse side effects, negative impact on breastfeeding, emergence of resistant microorganisms, and ineffectiveness of current antibiotics, have led individuals to seek alternative natural remedies. Hypericum perforatum (commonly known as St. John's Wort) is frequently used in the postpartum period due to its antimicrobial and antioxidant properties. This study aims to examine the effects of Hypericum perforatum on wound healing and pain in women following cesarean delivery.